Hepatitis C virus (HCV) remains a global public health problem even though more than 95%
of infections can be cured by treatment with direct-acting antiviral agents. Resolution of …

Despite the recent development of safe and highly effective direct-acting antivirals, hepatitis
C virus (HCV) infection remains a significant health problem. In 2016, the World Health …

Hepatitis C virus (HCV) is a major global health burden as the leading causative agent of
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …

The high genetic diversity of hepatitis C virus (HCV) complicates effective vaccine
development. We screened a cohort of 435 HCV-infected individuals and found that 2%–5 …

A functional adaptive immune response is the major determinant for clearance of hepatitis C
virus (HCV) infection. However, in the majority of patients, this response fails and persistent …

For any controlled human infection model (CHIM), a safe, standardized, and biologically
relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose …

Hepatitis C virus (HCV) is a major worldwide health burden, and a preventive vaccine is
needed for global control or eradication of this virus. A substantial hurdle to an effective HCV …

Hepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected
and is one of the most frequent indications for liver transplantation worldwide. Despite direct …

The introduction of direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment.
Short courses of treatment with these drugs are highly beneficial to patients, eliminating …

Serological assays detecting neutralising antibodies are important for determining the
immune responses following infection or vaccination and are also often considered a …